Cellectar Biosciences Stock (NASDAQ:CLRB)
Previous Close
$2.03
52W Range
$1.82 - $4.45
50D Avg
$2.09
200D Avg
$2.87
Market Cap
$82.35M
Avg Vol (3M)
$263.51K
Beta
0.99
Div Yield
-
CLRB Company Profile
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MNPR | Monopar Therapeutics Inc. |
| NXTC | NextCure, Inc. |
| PULM | Pulmatrix, Inc. |
| BPTH | Bio-Path Holdings, Inc. |
| CAPR | Capricor Therapeutics, Inc. |
| DFFN | CervoMed Inc. |
| TENX | Tenax Therapeutics, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| CBIO | Gyre Therapeutics, Inc. |
| BNTC | Benitec Biopharma Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| LBPH | Longboard Pharmaceuticals, Inc. |
| LUMO | Lumos Pharma, Inc. |